Niagen Bioscience, Inc. (NAGE)
| Market Cap | 295.30M -52.5% |
| Revenue (ttm) | 130.42M +20.8% |
| Net Income | 18.64M +32.1% |
| EPS | 0.21 +17.3% |
| Shares Out | 79.81M |
| PE Ratio | 17.62 |
| Forward PE | 17.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 815,465 |
| Open | 3.640 |
| Previous Close | 3.650 |
| Day's Range | 3.640 - 3.825 |
| 52-Week Range | 3.600 - 14.690 |
| Beta | 2.17 |
| Analysts | Strong Buy |
| Price Target | 12.60 (+240.54%) |
| Earnings Date | May 6, 2026 |
About NAGE
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-gra... [Read more]
Financial Performance
In 2025, Niagen Bioscience's revenue was $129.42 million, an increase of 29.95% compared to the previous year's $99.60 million. Earnings were $17.38 million, an increase of 103.30%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NAGE stock is "Strong Buy." The 12-month stock price target is $12.6, which is an increase of 240.54% from the latest price.
News
Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Niagen Bioscience (NAGE) to $11 from $12 and keeps a Buy rating on the shares. The company reported moderate revenue outperformance with…
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience price target lowered to $12 from $13 at Roth Capital
Roth Capital lowered the firm’s price target on Niagen Bioscience (NAGE) to $12 from $13 and keeps a Buy rating on the shares. The company’s Q1 results exceeded consensus estimates…
Niagen Bioscience reports Q1 EPS 7c, consensus 6c
Reports Q1 revenue $31.5M, consensus $31.03M. The company said, “We delivered $31.5 million of net sales and $6.3 million of net income for the first quarter. Our results reflect continued…
Niagen Bioscience sees 2026 sales growth 10%-15%
The company sees 2026 net sales increasing between 10%-15% year-over-year, excluding 2025 net sales attributable to the Analytical Reference Standards and Services segment, driven primarily by e-comme...
Niagen Bioscience Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 5% year-over-year to $31.5M, with net income of $6.3M and strong e-commerce growth. New product launches and a USP monograph for Niagen highlight innovation, while increased NMN competition and higher marketing spend present challenges.
Niagen Bioscience Quarterly report: Q1 2026
Niagen Bioscience has published its Q1 2026 quarterly earnings report on May 6, 2026.
Niagen Bioscience Earnings release: Q1 2026
Niagen Bioscience released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Niagen Bioscience Slides: Q1 2026
Niagen Bioscience has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total...
Niagen Bioscience price target lowered to $10 from $13 at Canaccord
Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $10 from $13 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1…
Niagen Bioscience launches Niagen Plus telehealth plarform
Niagen Bioscience (NAGE) announced the launch of its clinician-directed telehealth platform under Niagen Plus, enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade ...
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #AtHomeInjection--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy...
Niagen Bioscience Proxy statement: Proxy filing
Niagen Bioscience filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Niagen Bioscience Proxy statement: Proxy filing
Niagen Bioscience filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Niagen Bioscience announces new partnership with Olympia Pharmaceuticals
Niagen Bioscience (NAGE) announced a new partnership with Olympia Pharmaceuticals to compound and distribute pharmaceutical-grade Niagen for the Company’s Niagen Plus intravenous and injectable produc...
Niagen Bioscience announces new partnership with Olympia Pharmaceuticals
Niagen Bioscience (NAGE) announced a new partnership with Olympia Pharmaceuticals to compound and distribute pharmaceutical-grade Niagen for the Company’s Niagen Plus intravenous and injectable produc...
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience collaborates with USP to establish USP monograph
Niagen Bioscience (NAGE) announces that Nicotinamide Riboside Chloride, NRCI, the patented form of nicotinamide riboside in the Company’s flagship ingredient, Niagen, now has a published United States...
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen announces first cruise ship clinic partnership with OneSpaWorld
Niagen Bioscience (NAGE) announced OneSpaWorld (OSW) as the newest Niagen Plus provider, engaged to offer pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Mark...
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience increases share repurchase program to $20M
Niagen Bioscience (NAGE) announced that its board of directors has authorized an increase to the company’s previously disclosed share repurchase program, raising the total authorization from $10M to $...
Niagen Bioscience Increases Share Repurchase Program to $20 Million
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...